Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer

Overview

Journal J Oncol

Specialty Oncology

Date 2021 Mar 1

PMID 33643409

Citations 4

Authors

Dongfang Chen

Jianlin Xu

Rong Qiao

Yizhuo Zhao

Tianqing Chu

Baohui Han

Runbo Zhong

Affiliations

Soon will be listed here.

Abstract

Some studies have revealed that specific genetic mutations could be associated with chemotherapy response or even survival in small-cell lung cancer (SCLC). Our retrospective study aimed to identify the correlation between genetic mutations and progression-free survival (PFS) in extensive-stage SCLC after first-line chemotherapy. A total of 75 patients with extensive-stage SCLC confirmed by histopathology from February 2018 to February 2019 were retrospectively analyzed. The biopsy specimens of all patients were analyzed by Next-Generation Sequencing (NGS). All patients received first-line chemotherapy and follow-up at Shanghai Chest Hospital. Eleven genes were mutated in, at least, 10% of the 75 patients, including (96%), (77%), (32%), (21%), (16%), (16%), (15%), (15%), (15%), (13%), and (10%). The median number of mutated genes among all patients was 5. Patients with more than 5 mutated genes (PFS = 6.7 months, =0.004), mutant (PFS = 5.0 months, =0.011), and mutant (PFS = 6.7 months, =0.046) had better PFS after first-line chemotherapy than other patients. Multivariate Cox regression analysis showed that patients who achieved a PR (HR 3.729, 95% CI 2.038-6.822), had more than 5 mutated genes (HR 1.929, 95% CI 1.096-3.396), had mutations (HR 4.581, 95% CI 1.721-12.195), and had no liver metastasis (HR 0.415, 95% CI 0.181-0.951) showed improvements in PFS after first-line chemotherapy. In conclusion, the number of mutated genes and mutation status in extensive-stage SCLC were significantly related to PFS after first-line chemotherapy.

Citing Articles

An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.

Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M Int J Mol Sci. 2024; 25(16).

PMID: 39201255 PMC: 11354135. DOI: 10.3390/ijms25168568.

Exploring the correlation between HER2 alterations and F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients.

Ruan M, Chang C, Sun J, Liu L, Wang L, Lei B J Cancer Res Clin Oncol. 2023; 149(16):14493-14507.

PMID: 37572120 DOI: 10.1007/s00432-023-05218-8.

Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report.

Zhang M, Tang Y, Wang J, Liu Q, Xia B Front Oncol. 2022; 12:1024655.

PMID: 36387208 PMC: 9643274. DOI: 10.3389/fonc.2022.1024655.

Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.

Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R Cancer Med. 2022; 12(5):5372-5383.

PMID: 36250532 PMC: 10028028. DOI: 10.1002/cam4.5360.

References

Haeger S, Thompson J, Kalra S, Cleaver T, Merrick D, Wang X . Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene. 2015; 35(5):577-586. PMC: 4615192. DOI: 10.1038/onc.2015.112. View

Dowlati A, Lipka M, McColl K, Dabir S, Behtaj M, Kresak A . Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol. 2016; 27(4):642-7. PMC: 4803453. DOI: 10.1093/annonc/mdw005. View

Arriola E, Canadas I, Arumi M, Rojo F, Rovira A, Albanell J . Genetic changes in small cell lung carcinoma. Clin Transl Oncol. 2008; 10(4):189-97. DOI: 10.1007/s12094-008-0181-1. View

Yang S, Zhang Z, Wang Q . Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019; 12(1):47. PMC: 6498593. DOI: 10.1186/s13045-019-0736-3. View

Neal J, Gubens M, Wakelee H . Current management of small cell lung cancer. Clin Chest Med. 2011; 32(4):853-63. DOI: 10.1016/j.ccm.2011.07.002. View

Kahnert K, Kauffmann-Guerrero D, Maria Huber R . SCLC-State of the Art and What Does the Future Have in Store?. Clin Lung Cancer. 2016; 17(5):325-333. DOI: 10.1016/j.cllc.2016.05.014. View

Le Gallo M, Lozy F, Bell D . Next-Generation Sequencing. Adv Exp Med Biol. 2016; 943:119-148. DOI: 10.1007/978-3-319-43139-0_5. View

Rudin C, Awad M, Navarro A, Gottfried M, Peters S, Csoszi T . Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21):2369-2379. PMC: 7474472. DOI: 10.1200/JCO.20.00793. View

Wheatley-Price P, Ma C, Ashcroft L, Nankivell M, Stephens R, White S . The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Ann Oncol. 2009; 21(2):232-237. DOI: 10.1093/annonc/mdp300. View

10.

Foy V, Schenk M, Baker K, Gomes F, Lallo A, Frese K . Targeting DNA damage in SCLC. Lung Cancer. 2017; 114:12-22. DOI: 10.1016/j.lungcan.2017.10.006. View

11.

Tong B, Zhao J, Wang M . [Advances on Driver Mutations of Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2016; 19(4):236-40. PMC: 5999810. DOI: 10.3779/j.issn.1009-3419.2016.04.10. View

12.

Sun J, Choi Y, Ji J, Ahn J, Kim K, Han J . Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol. 2014; 26(1):161-166. DOI: 10.1093/annonc/mdu504. View

13.

Alves R, Meurer R, Roehe A . MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study. J Cancer Res Clin Oncol. 2014; 140(12):2021-5. DOI: 10.1007/s00432-014-1769-1. View

14.

Li M, Lin A, Luo P, Shen W, Xiao D, Gou L . mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer. Aging (Albany NY). 2020; 12(2):1285-1303. PMC: 7053592. DOI: 10.18632/aging.102683. View

15.

Semenova E, Nagel R, Berns A . Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015; 29(14):1447-62. PMC: 4526731. DOI: 10.1101/gad.263145.115. View

16.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

17.

van Meerbeeck J, Fennell D, De Ruysscher D . Small-cell lung cancer. Lancet. 2011; 378(9804):1741-55. DOI: 10.1016/S0140-6736(11)60165-7. View

18.

Reck M, Schenker M, Lee K, Provencio M, Nishio M, Lesniewski-Kmak K . Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019; 116:137-147. DOI: 10.1016/j.ejca.2019.05.008. View

19.

Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S . Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis. 2015; 36(6):616-21. PMC: 4462675. DOI: 10.1093/carcin/bgv026. View

20.

Peifer M, Fernandez-Cuesta L, Sos M, George J, Seidel D, Kasper L . Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44(10):1104-10. PMC: 4915822. DOI: 10.1038/ng.2396. View